Introduction
EphA2 belongs to the large Eph family of receptor tyrosine kinases, which are known to participate in various developmental processes including mammary epithelial growth and branching morphogenesis and patterning of the visual system (Andres et al., 1994; Ganju et al., 1994; Ruiz and Robertson, 1994; Connor et al., 1998; Moore-Scott et al., 2007; Vaught et al., 2009) . Like other developmental genes, EphA2 has also been implicated in tumor formation. The EPHA2 locus maps to chromosomal region 1p36, which is a region frequently altered in tumors of neuroectodermal origin such as neuroblastoma and melanoma (Sulman et al., 1997) . Earlier studies have reported that EphA2 is overexpressed in many cancer types including cutaneous melanoma (Nemoto et al., 1997; Easty et al., 1999; Walker-Daniels et al., 1999; Zelinski et al., 2001; Seftor et al., 2002; Hendrix et al., 2003; Miyazaki et al., 2003; Kataoka et al., 2004; Lu et al., 2008; Kamat et al., 2009; Cui et al., 2010; Liu et al., 2010) . There is some evidence that EphA2 may be involved in tumor cell differentiation (Bogan et al., 2009) and plasticity . Mechanistically, both kinase-dependent and -independent roles for EphA2 have been implicated in cancer progression . Also, EphA2 appears to participate in cross-talk between the Ras-PI3k-Akt and Ras-MAPK pathways (Menges and McCance, 2008) . In melanomas, EphA2 levels correlate with aggressiveness (Hess et al., 2006) , although lucid details of its downstream effects are still lacking. Of note, Margaryan et al. (2009) recently showed that downregulation of EphA2 in C8161 melanoma cells by antisense oligonucleotides led to suppression of growth.
In a separate but related line of investigation, we recently found that EphA2 is an essential mediator of apoptosis in response to ultraviolet radiation (Zhang et al., 2008) -the leading environmental carcinogen involved in melanoma formation. We reported that the ultraviolet radiation-mediated upregulation of EphA2 occurs in human melanocytes, keratinocytes and murine fibroblasts in a p53-independent, but MAPK-dependent mechanism (Yang et al., 2006; Zhang et al., 2008) . We also showed that ectopic expression of EphA2 without ultraviolet radiation led to a brisk induction of apoptosis in primary melanocytes. Given the seemingly paradoxical nature of EphA2's acute apoptotic effects in melanocytes and its correlation to aggressiveness in melanoma cells, we set out to investigate the impact of EphA2 on melanoma cell survival and tumorigenicity. Our results suggest that melanoma cells, which harbor high EphA2 levels, are in fact 'addicted' to this prosurvival factor, thereby positioning EphA2 as a bona fide melanoma oncogene.
Results

Melanoma cells often exhibit high levels of EphA2
In previous studies (Yang et al., 2006) , we showed a trend towards higher EphA2 transcript levels in melanoma cells compared with non-transformed melanocytes. To expand upon this characterization at the protein level, we tested a panel of 17 melanoma cell lines ( Figure 1a ) and found that most melanoma lines (11/17) exhibited much higher levels of EphA2 expression compared with melanocytes. Analysis of the EPHA2 locus in these cell lines did not show any evidence of amplification by single-nucleotide polymorphism-comparative growth hybridization (SNP-CGH) arrays (data not shown).
Three of 17 lines showed relatively low expression (C32, Mel-Juso, MEWO), whereas another three lines lacked any appreciable amounts of EphA2 (WM164, SK-Mel-119 and K19) altogether. As there was no evidence of EPHA2 deletion by SNP-CGH in these nonexpressors (data not shown), we speculated that at least some melanoma cell lines may have epigenetically silenced EPHA2. As shown in Figure 1b , the addition of 5 0 -aza 2 0 -deoxycytidine increased EphA2 in the low expression melanoma cells, but not in the immortalized normal human melanocytes (NHMs). However, when proliferation was scored, there was a general trend towards growth suppression, although these results are hard to interpret given the non-selective nature of 5 0 -aza 2 0 -deoxycytidine treatment (Supplementary Figure 1) . Overall, these observations suggest that some melanomas do not require EphA2 for survival, whereas others may possibly depend on EphA2 for growth. To directly test the latter hypothesis, we set out to selectively deplete EphA2 in several high-expressing lines.
EphA2 is essential for melanoma survival and tumorigenicity
To assess for survival, we selectively suppressed EphA2 in three independent cell lines using short hairpin RNA (shRNA) against the molecule (Figure 2a ). Within 96 h after infection, there was a dramatic increase in apoptosis in all three lines as measured by the percentage of cells in sub-G1 fraction (Figure 2b ; whole tracings Supplementary Figure 2 ) and the percentage of fluorescein isothiocyanate (FITC)-Annexin-positive cells (Figure 2c ). Consonant with these apoptotic effects, cellular viability was also significantly impaired ( Figure 2d ) along with colony formation (Figure 2e ).
We then speculated that p53 might be involved in the early apoptotic signal upon EphA2 deprivation. As shown in Figure 3a , EphA2 downregulation in UACC903 cells (TP53 wild type) led to a concomitant increase in p53, a finding replicated in two additional melanoma lines (Figure 3b , western analysis; Supplementary Figure 3 ). However, does the apoptotic response due to EphA2 withdrawal require p53? In p53-depleted A375 melanoma cells (A375 shp53 ; Figure 3c , lanes 2 and 4), there was still a comparable increase in apoptosis when EphA2 was suppressed ( Figure 3d ), although the induction of p53 was appropriately blunted ( Figure 3c , lanes 3 vs 4). It is worth noting that the constitutive levels of EphA2 appear to be lower in the A375 shp53 cells consistent with previous evidence that EphA2 is also regulated by p53 (Dohn et al., 2001) . These results speak to a complex interaction between EphA2 and p53, and that the observed cellular effects of EphA2 withdrawal are not solely due to p53.
As shown in Figure 4a , transient EphA2 silencing in MM455 and WM115 cells significantly reduced transwell migration compared with control cells (P ¼ 0.0005 and 0.009, respectively). Moreover, in three-dimensional cultures, reduction in EphA2 levels correlated with a loss of anchorage-independent growth (Figure 4b ). To further validate EphA2 addiction in vivo, we next determined the effect of EphA2 suppression on tumorigenicity ( Figure 4c ). Compared with UACC903 shCON cells, when UACC903 shEphA2 cells were injected into female Balb/C nude mice, there was a highly significant decrease in tumor formation (average tumor volume 394.4 vs 21.32 mm 3 , Po0.001). Taken together, these in vitro and in vivo assays support the contention that EphA2 is a potent determinant of invasiveness and survival in melanoma and that a percentage of these tumors can be considered dependent on this oncogene.
Ectopic expression of EphA2 in melanoma cells promotes a more malignant phenotype
We next sought to study the effects of overexpressing EphA2 in non-expressing cells. Immediately after the introduction of EphA2 into non-transformed immortalized melanocytes, there was a notable increase in the sub-G1 fraction, which was additive with ectopic Braf V600E expression ( Figure 5a ). This acute apoptotic effect was noted in our previous studies (Zhang et al., 2008) .
To investigate EphA2's longer-term effects, we selected two melanoma lines with low endogenous EphA2 (that is, WM164 and SK-Mel-119; Figure 1 ) and stably introduced EphA2. As shown in Figure 5b , Figure 1 EphA2 is overexpressed in a majority of melanoma lines. (a) Western analysis showing the relative protein levels of EphA2 in NHMs, immortalized NHMs (pMel) and a collection of 17 melanoma lines as indicated; melanoma lines with a BRAF mutation are designated by an asterisk. The vertical lines separate the melanocytes from the melanomas; both were analyzed on the same gel but in discontinuous lanes. (b) Treatment of immortalized NHMs (pMel) and three melanoma lines (K19, SK-Mel 119 and MEWO) with 5 0 -aza-2 0 -deoxycytidine for 48 h lead to increased EphA2 in the three melanoma lines, but not in the melanocytes.
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D Udayakumar et al both WM164 EphA2 and SK-Mel-119 EphA2 cells exhibited significantly higher proliferation rates (1.33-and 1.45fold, respectively) compared with their vector control counterparts. EphA2 expression also led to significant increases in colony formation for both cell lines (WM164, P ¼ 0.015 and SK-Mel-119, P ¼ 0.012; Figure 5c ). Lastly, we also found increased chemotactic migration in response to NIH3T3-conditioned media, a rich source of matrix proteins including fibronectin and vitronectin (Albini et al., 1987) (Figure 5d ) along with enhanced random migration in the scratch assay (Supplementary Figure  5) . The increased migration is also preserved even in the presence of mitomycin C ( Supplementary Figure 4) . (c) EphA2 downregulation induces apoptosis in human melanoma cells. FITC-Annexin and PI staining of melanoma cells, as indicated, after suppression by EphA2 shRNAs. In the two cell lines shown, apoptosis was increased more than 25% at 72 h after EphA2 downregulation. The sh-6405 was selected for further analysis and indicated as shEphA2. (d) EphA2 depletion also led to diminished cell viability as measured by AlamarBlue metabolic labeling (in triplicate) and (e) reduced colony formation (P ¼ 0.002; two-tailed t-test).
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Discussion
The Eph system has been implicated in various cellular processes ranging from control of normal development, angiogenesis and vascularization (Walker-Daniels et al., 2003) to oncogenesis of various tumor types (Nemoto et al., 1997; Miyazaki et al., 2003; Kataoka et al., 2004; Han et al., 2005; Herath et al., 2006) including melanoma (Easty et al., 1999; Hendrix et al., 2003; Walker-Daniels et al., 2003) . In this study, we performed a comprehensive phenotypic analysis of EphA2 functionality and provide substantiating evidence that EphA2 is an essential survival factor in a subset of melanomas.
The most striking finding is the profound loss of viability and tumorigenicity in melanoma cells upon depletion of EphA2 levels; a subset of melanomas is thus clearly 'addicted' to this oncogene. We also found an effect on migration and invasion in melanoma cells. This echoes some recent findings where EphA2 was reported to also promote migration of glioma and prostate cancer cells in a ligand-independent manner (Miao et al., 2009 ). Miao et al. (2009) further implicated PTEN loss and Akt-mediated phosphorylation of EphA2 in their mechanism. Interestingly, in our melanomas, the three cell lines that showed profound growth suppression by EphA2 depletion all harbor PTEN lesions-one mutation (UACC903-p.Y76X) and two deletions (WM115del Exon6 ; MM455-del Exon6 ) (Tsao et al., 2004) . Although differences in EphA2 function may exist between tumor cell types (glioma vs melanoma) and or physiological effects (migration vs survival), some element of mechanistic overlap is also likely.
Introduction of EphA2 into low-expressing melanoma cells enhanced proliferation, invasiveness and colony formation. With the absence of frequent structural changes at the EPHA2 locus (that is, amplification or recurrent mutations), EPHA2 belongs to a class of growth-promoting oncogenes distinct from BRAF V600E or NRAS Q61 . EphA2's survival influence is likely mediated through quantitative, rather than qualitative, changes.
As shown in our previous study (Zhang et al., 2008) and replicated in the current one, acute overexpression of EphA2 in non-transformed melanocytes elicited an apoptotic response; this effect is similar to and additive with those observed for acute Braf V600E expression ( Figure 5a) . It thus appears that, in the proper cellular context, EphA2 can behave as both a pro-apoptotic factor and a pro-survival factor. One potential unifying model is that of 'oncogene overdose addiction'. In other words, cells that develop compensatory mechanisms to survive the oncogenic stress conferred by EphA2 induction subsequently become reliant upon the survival-promoting effects of EphA2. This life/death duality is not unique to EphA2. Both apoptosis (Wajapeyee et al., 2008) and addiction (Hingorani et al., 2003; Wellbrock et al., 2004) have also been associated with 
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D Udayakumar et al the common melanoma oncogene, Braf V600E . Also, in a recent study of the prototypic death receptor, CD95 (that is, Fas or APO-1), abrogation of CD95 expression resulted in substantial growth retardation of ovarian, colon, liver, renal and breast cancer lines (Chen et al., 2010) ; these various tumors have apparently come to rely on some element of the 'pro-apoptotic' CD95 system for survival. Thus, susceptible cells that succumb to an initial oncogenic stress or pro-apoptotic signal (that is, 'overdose') may be less adapted for survival and purged from the tumor population; the stress-resistant cells exist in a genetic context, which favors oncogenic signaling and then become reliant on the oncogene for growth (that is, 'addiction'). Although many melanoma lines exhibit greater expression of EphA2 compared with non-transformed melanocytes, some cells appear to epigenetically silence EPHA2. The control of intracellular EphA2 levels is Involvement of EphA2 in melanoma oncogenesis D Udayakumar et al clearly complex and may be heterogeneous even within a single tumor. There are recent results showing that EphA2 levels may be higher among ulcerated and mitogenic melanomas (Straume and Akslen, 2002) and along invasive fronts of the tumor (Margaryan et al., 2009) ; however, overall prognosis does not appear to be influenced by EphA2 expression (Straume and Akslen, 2002) . Given the large number of Eph receptor tyrosine kinases, it is possible that other members of the Eph family may be the source of oncogenic sustenance in cells where EphA2 is not expressed.
In summary, we provide compelling data that EphA2 behaves as an essential survival factor in melanoma cells. In cells that overexpress EphA2, genetic suppression of the molecule leads to rapid loss of viability. However, in non-transformed cells, acute induction of EphA2 triggers a profound apoptotic response that may purge a less adaptive population of cells, thereby 
D Udayakumar et al establishing one possible mechanism of melanocytic tumor promotion after UV exposure. This overdoseaddiction model could potentially be leveraged for therapeutic gain in the clinical setting.
Materials and methods
Antibodies and inhibitors
Antibodies used in this study were as follows: polyclonal anti-EphA2 (C-20), mouse monoclonal anti-p53 (Santa Cruz Biotechnology, Santa Cruz, CA, USA), goat anti-mouseconjugated horseradish peroxidase and goat anti-rabbit immunoglobulin G-horseradish peroxidase (Cell Signaling Technologies, Beverly, MA, USA).
Cell culture
Both NHMs (Invitrogen, Gibco Cell Culture, Portland, OR, USA) and immortalized NHMs (gift from Hans Widlund, Harvard Medical School, Boston, MA, USA) were maintained in Medium-254 (Invitrogen, Gibco Cell Culture) supplemented with human melanocyte growth supplement and 1% penicillin/ streptomycin. Melanoma cell lines were maintained in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum (Atlanta Biologicals, Lawrenceville, GA, USA) containing 1% penicillin/streptomycin. Cells were treated with methylation inhibitor 5 0 -aza-2 0 -deoxycytidine (Sigma Aldrich, St Louis, MO, USA) at the indicated concentrations for 48 h.
Immunoblot analysis
Sodium dodecyl sulfate-polyacrylamide gel electrophoresis was carried out according to standard protocols. Total cell lysates (20-25 mg) were diluted in 6 Â Laemmli buffer (Boston Bioproducts Inc., Ashland, MA, USA) and loaded onto 4-20 or 10% precast gels (Bio-Rad Laboratories, Hercules, CA, USA), transferred onto nitrocellulose membrane (Bio-Rad Laboratories) and blocked with 5% non-fat milk (Bio-Rad Laboratories) in Tween 0.1%/TBS or 5% BSA (Fisher Scientific, Pittsburgh, PA, USA) in TBS/Tween 20 0.1%. Primary antibody dilutions used in this study were as follows: polyclonal anti-EphA2 (1:300) and polyclonal anti-p53 (1:500). Loading equivalence was monitored with monoclonal anti-a-tubulin (1:150) or monoclonal anti-GAPDH (1:3500) and gels were visualized by enhanced chemiluminescence (GE Healthcare formerly, Amersham Bioscience, Piscataway, NJ, USA) after application of 1:2000 goat antirabbit-horseradish peroxidase or goat anti-mouse horseradish peroxidase.
Plasmid construction and transfection
The eukaryotic expression plasmid of the human EPHA2 gene used in this study was generated previously in our laboratory (Zhang et al., 2008) . The cell lines were transfected with 4 mg of the EphA2 plasmid or the control vector using either Lipofectamine (Invitrogen, Carlsbad, CA, USA) or the Nucleofector (Lonza, Walkersville, MD, USA) according to the manufacturer's protocols. The cells were lysed with radioimmunoprecipitation assay buffer and the extracts were either collected at 48 h for analysis or the cells were trypsinized and re-plated at 1:10 dilution and selected with G418 (1 mg/ml) for stable incorporation. The stable clones were isolated at 14 days and the protein expression levels were confirmed with immunoblotting as described above.
Cell viability assay
The melanoma cells were plated in 96-well plates at a density of 1 Â 10 4 cells per well in corresponding growth media in triplicates. After 24 h, AlamarBlue reagent (Invitrogen) was added at 1:10 (reagent: volume of media in the well) dilution and incubated at 37 1C for 48 h. The fluorescence intensity measured at excitation wavelength of 550 nm and emission at 590 nm.
Gene silencing
Hairpin shRNAs targeting EphA2 (five clones) mRNA were purchased from Open Biosystems (Huntsville, AL, USA). The shRNA plasmids were mixed with the lentivirus packaging plasmids (Invitrogen) in the ratio according to the manufacturer's protocol. They were then mixed with Lipofectamine 2000 (Invitrogen) and transfected into 293 T cells for 48 h to generate virus. After 48 h, the viral supernatants were filtered and used for target cell infection in the presence of 8 mg/ml Polybrene (American Bioanalytical, Natick, MA, USA). Infection was maintained for 24 h and the cells were selected with puromycin and experiments were performed after selection. Small interfering RNAs (Ambion/Applied Biosystems, Austin, TX, USA) were nucleofected using the Lonza protocol; these experiments were carried out 24-48 h postnucleofection.
Cell proliferation and colony formation assay For assaying proliferation, cells were plated on 24-well cell culture plates (Corning Inc., Corning, NY, USA), 4 Â 10 4 cells were plated per well in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine. Cells were then counted on the days indicated in the respective figures. For colony formation assays, the cells were plated in six-well plates at a density of 400 cells per well. The media were changed every other day and colonies were counted at day 14 after staining with 0.05% crystal violet. The experiments were carried out in triplicates and the results were validated with two different cell lines.
Migration assays: scratch migration and Boyden chamber transwell migration assay Scratch migration assay, an in vitro wound model, was performed as described (Liang et al., 2007) . Briefly, cells were grown to confluence in 12-well culture plates (Corning Inc.). A wound was then created by scratching across the well with a thin pipette tip. Cells were then washed once with phosphatebuffered saline, re-nourished with fresh media and monitored for 72 h. The migration of cells was recorded by phase-contrast microscopy (Carl Zeiss Inc., Dublin, Ireland) at time 0 (immediate after the scratch) and every 24 h for 3 days.
The area of open gap left was measured using the software ImageJ. Chemotactic migration assay was performed using 24-well transwell inserts with 8 mm membrane. A total of 1 Â 10 5 cells were placed on the top of the chamber in media supplemented with 0.1% fetal bovine serum and NIH3T3 conditioned media were applied on the bottom chamber. The cells were allowed to migrate at 37 1C for 4 h; subsequently, the bottom side of the membrane was stained with crystal violet and the migrated cells were counted under an inverted microscope. The assays were carried out in duplicate.
Three-dimensional organotypic cultures and the anchorageindependent growth assay The three-dimensional cultures were carried out as described (Debnath et al., 2003) . The cells were plated on a mixture of Involvement of EphA2 in melanoma oncogenesis D Udayakumar et al collagen:matrigel (Becton Dickinson Biosciences, San Jose, CA, USA) in the ratio 1:1 and monitored for 10-14 days. The cells were fixed with 100% methanol at À20 1C for 20 min, followed by staining by immunofluorescence. The cells were blocked with 5% goat serum/phosphate-buffered saline/Triton X-100 blocking solution and the primary antibody incubated overnight. FITC-anti-mouse secondary antibody and 4 0 ,6 0diamidino-2-phenylindole were used to label the cells, which were then visualized with a confocal imaging system (Olympus, Center Valley, PA, USA). Anchorage-independent growth was assessed by growing the cells in ultra-low attachment tissue culture plates for 4-6 days, followed by visualization with an inverted microscope (Olympus).
Cell viability analysis: Annexin-FITC staining and propidium iodide staining For cell cycle analysis and propidium iodide (PI) staining, 1 Â 10 6 cells were harvested and then fixed with 70% ice-cold ethanol overnight. After fixation, cells were washed with phosphate-buffered saline and then stained with 100 mg/ml PI in phosphate-buffered saline containing 100 mg/ml RNase A and 0.1% NP40 (all from Sigma). PI-stained cells were analyzed by FACSCalibur (Becton Dickinson Biosciences).
For quantitation of apoptotic cell death, the Annexin IV-FITC Apoptotic Kit was used (Becton Dickinson Biosciences). Cells were trypsinized, collected, washed twice with 1 Â binding buffer provided with the kit, incubated with 5 ml each of FITC-Annexin and PI (reference for dead cells) for 15 min at room temperature, diluted with binding buffer and analyzed by FACSCalibur within 1 h of staining.
In vivo mice tumor studies Experiments involving mice were approved by the Institutional Animal Care and Use Committee, at the Massachusetts General Hospital. A total of 1 Â 10 6 UACC903 melanoma cells (with or without EphA2 overexpression) were injected into the subcutaneous region of the Balb/c female nu/nu mice, and the tumors were allowed to grow. Four mice were used for each category. Palpable tumors were measured between 4 and 8 weeks. At 8 weeks, the mice were killed, and the tumor size was measured with microcalipers and recorded. The final tumor volume was calculated by multiplying the height, length and width of each tumor, expressed as mm 3 .
